利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

99 条记录 (耗时 0.079 秒)

    Hepatitis C virus inhibitors
    41.
    发明授权
    Hepatitis C virus inhibitors 有权

    公开(公告)号：US08815928B2

    公开(公告)日：2014-08-26

    申请号：US12879028

    申请日：2010-09-10

    申请人： Yat Sun Or ,  Lu Ying ,  Xiaowen Peng ,  Ce Wang ,  Yao-Ling Qiu

    发明人： Yat Sun Or ,  Lu Ying ,  Xiaowen Peng ,  Ce Wang ,  Yao-Ling Qiu

    IPC分类号： A61K31/4178 ,  C07D403/10

    CPC分类号： C07D401/14 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C12N2770/24211

    摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with the compounds.

    Linked diimidazole derivatives
    43.
    发明授权
    Linked diimidazole derivatives 有权
    连接的二咪唑衍生物

    公开(公告)号：US08637561B2

    公开(公告)日：2014-01-28

    申请号：US12707200

    申请日：2010-02-17

    申请人： Yao-Ling Qiu ,  Lu Ying ,  Ce Wang ,  Xiaowen Peng ,  Yat Sun Or

    发明人： Yao-Ling Qiu ,  Lu Ying ,  Ce Wang ,  Xiaowen Peng ,  Yat Sun Or

    IPC分类号： A61K31/4178 ,  C07D403/10 ,  C07D403/12

    CPC分类号： C07D403/14 ,  A61K38/21 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07F9/65583 ,  A61K2300/00

    摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

    摘要翻译： 本发明公开了式（I）化合物或其药学上可接受的盐，酯或前药：其抑制含RNA病毒，特别是丙型肝炎病毒（HCV）。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    SUBSTITUTE PYRROLIDINE DERIVATIVES
    49.
    发明申请
    SUBSTITUTE PYRROLIDINE DERIVATIVES 审中-公开
    替代吡咯烷衍生物

    公开(公告)号：US20090053175A1

    公开(公告)日：2009-02-26

    申请号：US12196642

    申请日：2008-08-22

    申请人： Yat Sun Or ,  Ce Wang ,  Jiang Long ,  Lu Ying ,  Yao-Ling Qiu

    发明人： Yat Sun Or ,  Ce Wang ,  Jiang Long ,  Lu Ying ,  Yao-Ling Qiu

    IPC分类号： A61K38/21 ,  C07D277/08 ,  C07D263/02 ,  C07D307/02 ,  C07D213/02 ,  A61K38/19 ,  A61P31/12 ,  A61K39/00 ,  A61K31/426 ,  A61K31/42 ,  A61K31/341 ,  A61K31/44

    CPC分类号： C07D417/14 ,  A61K38/21 ,  C07D401/14 ,  C07D403/06 ,  C07D405/14 ,  C07D409/14 ,  C07D413/04 ,  C07D417/04 ,  A61K2300/00

    摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

    摘要翻译： 本发明公开了式（I）化合物或其药学上可接受的盐，酯或前药：其抑制含RNA病毒，特别是丙型肝炎病毒（HCV）。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。 本发明涉及上文所示的新的抗病毒化合物，包含这些化合物的药物组合物，以及用于治疗或预防需要用所述化合物治疗的受试者中的病毒（特别是HCV）感染的方法。

    C-9 ALKENYLIDINE BRIDGED MACROLIDES
    50.
    发明申请
    C-9 ALKENYLIDINE BRIDGED MACROLIDES 有权
    C-9烯丙基嵌段共聚物

    公开(公告)号：US20080119418A1

    公开(公告)日：2008-05-22

    申请号：US11940766

    申请日：2007-11-15

    申请人： Ly Tam Phan ,  Yao-Ling Qiu ,  Yat Sun Or

    发明人： Ly Tam Phan ,  Yao-Ling Qiu ,  Yat Sun Or

    IPC分类号： A61K31/7052 ,  C07H17/08

    CPC分类号： C07D493/08 ,  C07D498/18

    摘要： The present invention discloses compounds of formulae (I), (II) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

    摘要翻译： 本发明公开了具有抗菌性能的式（I），（II）或其药学上可接受的盐，酯或前药的化合物。 本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。 本发明还包括制备本发明化合物的方法。